key: cord-1028635-y2qppg7u
authors: Tang, Ning
title: Response to “Lupus anticoagulant is frequent in patients with Covid‐19”
date: 2020-05-07
journal: J Thromb Haemost
DOI: 10.1111/jth.14890
sha: 8ce73b297fbd2df0d3c350b1b7819f6a3145a430
doc_id: 1028635
cord_uid: y2qppg7u

We appreciate the opportunity to respond to the letter from Dr. Inès Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti–β2‐glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID‐19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain.

: Letter to the Editor

We appreciate the opportunity to respond to the letter from Dr. Inès Harzallah, et al.

Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-β2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19

patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2] , the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain.

Both the ISTH and the Clinical and Laboratory Standards Institute (CLSI) guidelines have urged caution when interpreting LAC results on patients receiving anticoagulants [3, 4] . Given common use of low molecular weight heparin (LMWH) and unfractionated heparin for thromboprophylaxis in COVID-19 inpatients, false positive results due to interference of these anticoagulants may be an important reason for the high positive rate of LAC mentioned in this letter. It has been recommended that the blood should be drawn for LAC testing after 12 hours since the last dose of LMWH, and 24

hours since that of Rivaroxaban [3, 5] .

None declared.

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Accepted Article

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation

Update of the guidelines for lupus anticoagulant detection

Laboratory Testing for the Lupus Anticoagulant

False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome

This article is protected by copyright. All rights reserved Hubei, China Email: tonyjesus@126.com